Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: An immunohistochemical study

Pathology Research and Practice

Volumn 199, Issue 1, 2003, Pages 23-28

  Yamazaki, Kazuto ^a   Yajima, Takayuki ^b   Nagao, Toshitaka ^c   Shinkawa, Hiroki ^a   Kondo, Fukuo ^d   Hanami, Kyota ^a   Asoh, Akira ^a   Sugano, Isamu ^a   Ishida, Yasuo ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d Funabashi Central Hospital   (Japan)

Author keywords

E2F 1; MIB 1; Pancreatic ductal carcinoma

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; TRANSCRIPTION FACTOR E2F;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREAS SURGERY; PROTEIN EXPRESSION; SURVIVAL TIME; THEORY; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; UPREGULATION;

EID: 0037228893     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1078/0344-0338-00348     Document Type: Article

References (26)

1. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC, et al. (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64: 1076-1082
2. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32
3. Dyson N (1998) The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262
4. Fan J, Bertino JR (1997) Functional roles of E2F in cell cycle regulation. Oncogene 14: 1191-1200
5. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Jr., Livingston DM, Orkin SH, Greenberg ME (1996) E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85: 549-561
6. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG (2002) Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 198: 142-156
7. Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C, Harlow E (1993) Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev 7: 1850-1861
8. Johnson DG, Cress WD, Jakoi L, Nevins JR (1994) Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci (USA) 91: 12823-12827
9. Johnson DG, Schwarz JK, Cress WD, Nevins JR (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365: 349-352
10. Klöppel G, Solcia E, Longnecker DS, Capella C, Sobin LH (1996) Histological typing of tumors of the exocrine pancreas. 2nd ed. Springer, Berlin, Heidelberg, NewYork
11. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK (1998) Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol 11: 457-463
12. Linder S, Parrado C, Falkmer UG, Blasjo M, Sundelin P, von Rosen A (1997) Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumour material. Br J Cancer 76: 54-59
13. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C (1995) Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res 15: 2659-2668
14. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG (1998) Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci (USA) 95: 8858-8863
15. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Johnson DG (1999) E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol 19: 6408-6414
16. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G, Cordon-Cardo C (1999) Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 91: 874-881
17. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57: 1731-1734
18. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126-3130
19. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672-1677
20. Singh P, Wong SH, Hong W (1994) Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. Embo J 13: 3329-3338
21. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E (1999) Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 81: 535-538
22. Xu G, Livingston DM, Krek W (1995) Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci (USA) 92: 1357-1361
23. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T (1998) Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1 (+/-) mice. Nat Genet 18: 360-364
24. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ (1996) Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-548
25. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, Klein-Szanto AJ (2000) E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 9: 395-401
26. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ (2000) E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res 60: 5972-5976